Zobrazeno 1 - 10
of 154
pro vyhledávání: '"Laszlo, Urban"'
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-17 (2023)
Abstract In vitro secondary pharmacology assays are an important tool for predicting clinical adverse drug reactions (ADRs) of investigational drugs. We created the Secondary Pharmacology Database (SPD) by testing 1958 drugs using 200 assays to valid
Externí odkaz:
https://doaj.org/article/469239a27b5e405297285f43eadcea47
Autor:
Enriqueta Felip, Helena Linardou, Fabrice Barlesi, Michele Maio, Luis Paz-Ares, Jonathan W Goldman, Karim Vermaelen, Osvaldo Arén Frontera, Erika Rijavec, Kevin Jao, Clarisse Audigier-valette, Han Chang, David R Spigel, Neal E Ready, Tudor-Eliade Ciuleanu, María Rosario García Campelo, Stéphanie Bordenave, Laszlo Urban, Jean-Sébastien Aucoin, Cristina Zannori, Alessandra Curioni Fontecedro, Amparo Sánchez-Gastaldo, Oscar Juan-Vidal, Elena Poddubskaya, Samreen Ahmed, Sunney Li, Joseph Fiore, Angelic Acevedo
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss 2 (2023)
Background CheckMate 817, a phase 3B study, evaluated flat-dose nivolumab plus weight-based ipilimumab in patients with metastatic non-small cell lung cancer (NSCLC). Here, in this research, we report on first-line treatment in patients with Eastern
Externí odkaz:
https://doaj.org/article/299f8904a44340aa8e9fdf450ecbbc4b
Autor:
Julie R. Brahmer, Jong-Seok Lee, Tudor-Eliade Ciuleanu, Reyes Bernabe Caro, Makoto Nishio, Laszlo Urban, Clarisse Audigier-Valette, Lorena Lupinacci, Randeep Sangha, Adam Pluzanski, Jacobus Burgers, Mauricio Mahave, Samreen Ahmed, Adam J. Schoenfeld, Luis G. Paz-Ares, Martin Reck, Hossein Borghaei, Kenneth J. O'Byrne, Ravi G. Gupta, Judith Bushong, Li Li, Steven I. Blum, Laura J. Eccles, Suresh S. Ramalingam
Publikováno v:
Journal of Clinical Oncology. 41:1200-1212
PURPOSE We present 5-year results from CheckMate 227 Part 1, in which nivolumab plus ipilimumab improved overall survival (OS) versus chemotherapy in patients with metastatic non–small-cell lung cancer, regardless of tumor programmed death ligand 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d8b4a140d7d0dc05447ae536d36a8ed
https://doi.org/10.1200/jco.22.01503
https://doi.org/10.1200/jco.22.01503
Autor:
Vera Gorbunova, Vincent Giranda, Mark McKee, Peter Ansell, Hao Xiong, Juliann Dziubinski, Caroline Nickner, Jiang Qian, Qin Qin, Ulrich Keiholz, Ebenezer Kio, Fabrice Barlesi, Sergey Orlov, Laszlo Urban, Erzsebet Juhasz, C. Michael Jones, Martin Reck, Julien Mazieres, Normand Blais, Suresh S. Ramalingam
Purpose: PARP plays an important role in DNA repair. Veliparib, a PARP inhibitor, enhances the efficacy of platinum compounds and has been safely combined with carboplatin and paclitaxel. The primary endpoint of this phase II trial determined whether
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45e7ce0aeb342f5774b9143be1c1edd9
https://doi.org/10.1158/1078-0432.c.6526571.v1
https://doi.org/10.1158/1078-0432.c.6526571.v1
Autor:
Vera Gorbunova, Vincent Giranda, Mark McKee, Peter Ansell, Hao Xiong, Juliann Dziubinski, Caroline Nickner, Jiang Qian, Qin Qin, Ulrich Keiholz, Ebenezer Kio, Fabrice Barlesi, Sergey Orlov, Laszlo Urban, Erzsebet Juhasz, C. Michael Jones, Martin Reck, Julien Mazieres, Normand Blais, Suresh S. Ramalingam
Supplemental Table 1. Demographics and baseline characteristics by histology: squamous cell Supplemental Table 2. Demographics and baseline characteristics by histology: non-squamous cell Supplemental Table 3. Mean {plus minus} SD pharmacokinetic par
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62499efaffeb259872b1608c05230ee5
https://doi.org/10.1158/1078-0432.22467197
https://doi.org/10.1158/1078-0432.22467197
Autor:
Mateusz Maciejewski, Eugen Lounkine, Steven Whitebread, Pierre Farmer, William DuMouchel, Brian K Shoichet, Laszlo Urban
Publikováno v:
eLife, Vol 6 (2017)
The Food and Drug Administration Adverse Event Reporting System (FAERS) remains the primary source for post-marketing pharmacovigilance. The system is largely un-curated, unstandardized, and lacks a method for linking drugs to the chemical structures
Externí odkaz:
https://doaj.org/article/093147f8a3444b44bec422d9105175a0
Autor:
Lilla Tamási, Laszlo Urban, György Rokszin, Zsolt Abonyi-Tóth, Zoltán Kiss, Gyula Ostoros, Zsófia Nagy-Erdei, Zoltán Polányi, Judit Moldvay, Krisztián Horváth, Veronika Müller, Krisztina Bogos, Gabriella Gálffy, Zoltán Vokó, Nóra Bittner, Veronika Sárosi, Aladár Vastag, Balázs Nagy, Zsófia Barcza
Publikováno v:
Journal of Thoracic Oncology. 15:692-699
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19fb798d5c14d6861fb6b67ca2c90a53
https://doi.org/10.1016/j.jtho.2019.11.001
https://doi.org/10.1016/j.jtho.2019.11.001
Publikováno v:
Acta Universitatis Sapientiae: Agriculture and Environment, Vol 11, Iss 1, Pp 23-37 (2019)
The main objective of this paper is to report the effect of shrub removal, mowing, and grazing as grassland management methods on spider diversity. Sampling was conducted in the Mátra Mountains and four disturbed main road verges in Hungary. Shrub r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cbb9efa844356b44e51dc6cbd31389f5
https://doaj.org/article/adddd3083be944d58f73962e77e91ab9
https://doaj.org/article/adddd3083be944d58f73962e77e91ab9
Autor:
Gervais Tougas, Laszlo Urban, Dominique Brees, Salah-Dine Chibout, Marianne Uteng, Page Bouchard, Patrick Y. Muller, Gerd A. Kullak-Ublick
Publikováno v:
Drug Discovery Today. 24:285-292
With increasing expectations to provide evidence of drug efficacy, safety, and cost-effectiveness, best-in-class drugs are a major value driver for the pharmaceutical industry. Superior safety is a key differentiation criterion that could be achieved
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a2b55acca20d9c77f5250a0bd88fc2f
https://doi.org/10.1016/j.drudis.2018.09.009
https://doi.org/10.1016/j.drudis.2018.09.009
Autor:
Francois Pognan, Laszlo Urban, Heiko Schadt, Veronica V. Rezelj, Adolfo Garcia-Sastre, Olivier Schwartz, Blandine Monel, Nevan J. Krogan, Audrey Fischer, Ziyang Zhang, Brian K. Shoichet, Assaf Alon, Matthew J. O’Meara, Benoit Fischer, Kevan M. Shokat, Tia A. Tummino, Kris M. White, Marco Vignuzzi, Francesca Moretti, Jiankun Lyu, Thomas Vallet, Henry R. O’Donnell, Andrew C. Kruse
Publikováno v:
bioRxiv
article-version (status) pre
article-version (number) 1
article-version (status) pre
article-version (number) 1
Repurposing drugs as treatments for COVID-19 has drawn much attention. A common strategy has been to screen for established drugs, typically developed for other indications, that are antiviral in cells or organisms. Intriguingly, most of the drugs th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9022a1070b6eea488945070d6619e143
https://doi.org/10.1101/2021.03.23.436648
https://doi.org/10.1101/2021.03.23.436648